New immunomodulatory treatment protocol for canine leishmaniosis reduces parasitemia and proteinuria
PLOS Neglected Tropical Diseases · 2024
DOI: 10.1371/journal.pntd.0012712 ↗Kurz gefasst
Studienprotokoll in der Zeitschrift PLOS Neglected Tropical Diseases, 2024. Verfasst von Guadalupe Miró und 10 weiteren Autor:innen. Beteiligte Einrichtung: Animal Health Department, Veterinary School, Universidad Complutense de Madrid, Madrid Spain. Hauptthemen laut MEDLINE: Dog Diseases, Leishmaniasis, Allopurinol, Proteinuria. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 87 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
The current standard treatment for canine leishmaniosis (CanL), N-methylglucamine antimoniate (MGA) given with allopurinol, is not fully effective and may cause adverse effects and drug resistance. In vitro and in vivo studies have shown that nucleotides, administered alone or with AHCC, offer benefits in the treatment of CanL. This study examines the effects of a new immunomodulatory treatment protocol in which dietary nucleotides and AHCC are added to the recommended standard treatment. Out of 160 sick dogs with naturally occurring clinical leishmaniosis recruited, 97 were randomized to a supplement (n = 47) or control (n = 50) group. All dogs received an initial 28-day course of MGA and 365-day course of allopurinol. From day 0 to day 730, dogs in the control group additionally received a placebo, while dogs in the supplement group received Impromune (Bioiberica S.A.U., Esplugues de Llobregat, Spain), an oral supplement providing 32 mg/kg nucleotides and 17 mg/kg AHCC daily. After 2 years, five dogs had relapsed in the supplement group (18.5%) while seven did so in the control group (22.6%). Over time, animals in both groups showed significant improvements in body weight, LeishVet clinical stage, clinical score, and anti- Leishmania antibodies. Adding the supplement to the standard protocol resulted in further significant improvements, namely in reducing the parasite load and urinary protein/creatinine ratio, improving IRIS stage, lowering serum creatinine levels on day 30, deceasing urine turbidity on day 365, and improving weight gain on day 545. The daily intake of the supplement over two years proved safe and well tolerated. Our study confirms the efficacy of the recommended standard treatment for CanL, but also reveals that by adding Impromune additional benefits are obtained, especially reduced parasitemia and improved renal function.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Animal Health Department, Veterinary School, Universidad Complutense de Madrid, Madrid Spain.
- R&D Bioiberica S.A.U., Esplugues de Llobregat, Spain.
- Interlab-UMU, Campus de Excelencia "Mare Nostrum", University of Murcia, Campus Espinardo, Murcia, Spain.
- Departament de Medicina i Cirurgia Animals, Facultat de Veterinària, Universitat Autònoma de Barcelona, Bellaterra, Spain.
- Eurecat, Technology Centre of Catalonia, Technological Unit of Nutrition and Health, Reus, Spain.
- Hospital Clínic Veterinari, Universitat Autònoma de Barcelona, Bellaterra, Spain.
ORCID-Profile: Guadalupe Miró
Zitieren
APA
Miró, G., Segarra, S., Cerón, J. J., Ferrer, L., Solano-Gallego, L., Montell, L., Costa, E., Teichenne, J., Mariné-Casadó, R., GALILEI trial Group, & Roura, X. (2024). New immunomodulatory treatment protocol for canine leishmaniosis reduces parasitemia and proteinuria. PLOS Neglected Tropical Diseases. https://doi.org/10.1371/journal.pntd.0012712
Vancouver
Miró G, Segarra S, Cerón JJ, Ferrer L, Solano-Gallego L, Montell L, et al. New immunomodulatory treatment protocol for canine leishmaniosis reduces parasitemia and proteinuria. PLOS Neglected Tropical Diseases. 2024. doi:10.1371/journal.pntd.0012712
BibTeX
@article{Mir2024,
author = {Miró, Guadalupe and Segarra, Sergi and Cerón, José Joaquín and Ferrer, Lluís and Solano-Gallego, Laia and Montell, Laia and Costa, Ester and Teichenne, Joan and Mariné-Casadó, Roger and GALILEI trial Group, GALILEI trial Group and Roura, Xavier},
title = {New immunomodulatory treatment protocol for canine leishmaniosis reduces parasitemia and proteinuria},
journal = {PLOS Neglected Tropical Diseases},
year = {2024},
doi = {10.1371/journal.pntd.0012712}
}
EUVIMED